Turnaround time and barriers to treatment of newly diagnosed cancer in Uganda: a mixed-methods longitudinal study.
Turnaround time
Uganda
barriers
cancer
steps
waiting time
Journal
African health sciences
ISSN: 1729-0503
Titre abrégé: Afr Health Sci
Pays: Uganda
ID NLM: 101149451
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
entrez:
29
8
2022
pubmed:
30
8
2022
medline:
31
8
2022
Statut:
ppublish
Résumé
Cancer represents a growing public health concern. Late-stage at diagnosis, limited access to effective treatment, and loss to follow-up are responsible for dismal outcomes. To describe care pathways, turnaround times, and identify barriers to timely initiation of cancer treatment. Using a sequential mixed-methods design involving focus group discussions, we followed up 50 participants between January, and June 2018. We computed the median observed turnaround time to treatment (TTT) at each care step and reported delay as deviations from the proposed ideal turnaround times. The ideal TTT with either chemotherapy, or radiotherapy, or surgery was 8, 14, and 21 days respectively. At a median follow-up time of 35.5 days (IQR 17-66), only 29 of the 50 study participants had completed all steps between registration and initiation of treatment, and the observed median TTT was 16 days (9 - 22 days) for chemotherapy, and 30 days (17 - 49 days) for radiotherapy, reflecting a significant delay (p-value = 0.017). Reported barriers were; shortage of specialists, patients required visits to outside facilities for staging investigations, prohibitive costs, poor navigation system and time wastage. When compared to the recommended ideal turnaround time, there was significant institutional delay in access to chemotherapy and radiotherapy attributed to multiple external and internal healthcare system barriers.
Identifiants
pubmed: 36032470
doi: 10.4314/ahs.v22i1.40
pii: jAFHS.v22.i1.pg327
pmc: PMC9382503
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
327-337Informations de copyright
© 2022 Kibudde S et al.
Références
Gynecol Oncol Rep. 2018 Jan 05;24:30-35
pubmed: 29892691
Oncologist. 2016 Jun;21(6):731-8
pubmed: 27053501
Int J Womens Health. 2015 Aug 27;7:791-8
pubmed: 26346001
PLoS One. 2018 Apr 17;13(4):e0195986
pubmed: 29664956
Cancer. 2019 Jun 1;125(11):1918-1928
pubmed: 30840316
Eur J Cancer Care (Engl). 2015 Jul;24(4):503-13
pubmed: 24923866
Ecancermedicalscience. 2019 Jul 25;13:942
pubmed: 31552115
J Glob Oncol. 2019 Feb;5:1-8
pubmed: 30763144
Br J Med Med Res. 2014 May 1;4(13):2599-2610
pubmed: 25984460
Ecancermedicalscience. 2019 Jul 25;13:946
pubmed: 31552119
Breast Cancer Res. 2019 Aug 13;21(1):93
pubmed: 31409419
Transl Lung Cancer Res. 2019 Aug;8(4):380-391
pubmed: 31555513
Ecancermedicalscience. 2019 Nov 19;13:976
pubmed: 31921347
BMC Cancer. 2018 Mar 21;18(1):312
pubmed: 29562894
Health Educ Behav. 2016 Aug;43(4):420-7
pubmed: 27091222
PLoS One. 2019 Jul 11;14(7):e0219601
pubmed: 31295322
BMC Res Notes. 2013 Apr 08;6:136
pubmed: 23566436
BMC Public Health. 2019 Jul 29;19(1):1018
pubmed: 31357977
BMC Res Notes. 2015 Sep 22;8:467
pubmed: 26395344
Infect Agent Cancer. 2013 Sep 30;8(1):36
pubmed: 24079452